Patent Landscape Analysis: U.S. Patent 6,967,208
U.S. Patent 6,967,208, titled "Method for treating disorders with compounds that activate or modulate the activity of guanylate cyclase," claims methods for treating disorders by administering specific compounds that activate or modulate guanylate cyclase activity. The patent's core innovation lies in the therapeutic application of these compounds for conditions where increased cyclic guanosine monophosphate (cGMP) levels are beneficial.
What is the core invention claimed by U.S. Patent 6,967,208?
The primary invention of U.S. Patent 6,967,208 is a method of treatment utilizing compounds that modulate guanylate cyclase activity. Specifically, the patent claims:
- Method of treatment: Administering a therapeutically effective amount of a compound to a subject.
- Compound type: The compound is described as an organic molecule capable of activating or modulating the activity of guanylate cyclase. This enzyme is critical in the production of cyclic guanosine monophosphate (cGMP), a secondary messenger involved in numerous physiological processes, including smooth muscle relaxation, vasodilation, and cellular signaling [1].
- Therapeutic target disorders: The patent broadly covers the treatment of disorders where enhancing cGMP levels is therapeutically indicated. This includes but is not limited to cardiovascular diseases such as pulmonary hypertension and heart failure, as well as other conditions responsive to vasodilation and smooth muscle relaxation.
What is the scope of the claims in U.S. Patent 6,967,208?
The claims in U.S. Patent 6,967,208 are directed towards the method of using specific classes of compounds. The scope focuses on the therapeutic application rather than the compounds themselves, though the nature of the compounds is defined by their mechanism of action.
-
Claim 1: This independent claim defines a method for treating a disorder in a subject that is responsive to increased levels of cyclic guanosine monophosphate (cGMP). The method involves administering a therapeutically effective amount of a compound, which is an organic molecule that activates or modulates the activity of guanylate cyclase. The claim specifies that the compound is not a nitric oxide donor. This exclusionary clause is significant, distinguishing the patented method from established treatments relying on exogenous nitric oxide [1].
-
Dependent Claims: Several dependent claims further refine the scope by specifying characteristics of the compound, the disorders to be treated, or the route of administration.
- Compound Characteristics: Some dependent claims might specify structural features of the organic molecule or its pharmacological properties, such as its ability to stimulate soluble guanylate cyclase (sGC) [1].
- Disorder Specificity: Dependent claims can enumerate specific disorders, such as pulmonary hypertension, wherein the method is applied [1].
- Dosage and Administration: Claims may also detail the dosage range or the specific route of administration (e.g., oral, intravenous) that constitutes the claimed method [1].
The patent's scope is designed to cover a broad range of applications for compounds acting through guanylate cyclase modulation, provided they are not direct nitric oxide donors. This allows for protection of a therapeutic concept applicable to various drug candidates that fit the described mechanism.
What is the asserted mechanism of action for the compounds under U.S. Patent 6,967,208?
The asserted mechanism of action is the direct activation or modulation of guanylate cyclase (GC) enzyme activity. This contrasts with traditional therapies that rely on the generation of endogenous or exogenous nitric oxide (NO) to stimulate GC.
- Direct GC Activation: The compounds are described as directly interacting with the guanylate cyclase enzyme, enhancing its catalytic activity. This direct stimulation leads to an increased production of cyclic guanosine monophosphate (cGMP) within cells [1].
- cGMP Pathway: Elevated intracellular cGMP levels trigger downstream cellular effects, most notably smooth muscle relaxation. This vasodilation is the primary therapeutic benefit for cardiovascular disorders.
- Distinction from NO Donors: A crucial aspect of the patent's mechanism is its emphasis on compounds that are not nitric oxide donors. This means the compounds do not themselves release nitric oxide. Instead, they directly interact with GC, potentially bypassing the limitations or side effects associated with NO signaling, such as rapid metabolism and the need for specific physiological conditions for NO generation [1].
- Soluble Guanylate Cyclase (sGC): The patent primarily targets the soluble form of guanylate cyclase (sGC), a heme-containing enzyme that is the principal receptor for NO. Compounds that directly stimulate sGC can achieve similar physiological outcomes to NO but through a different molecular interaction.
What are the key chemical structures or classes of compounds potentially covered by the patent?
While U.S. Patent 6,967,208 focuses on the method of use, the definition of the "organic molecule" that activates guanylate cyclase implicitly defines the types of chemical structures that fall within its purview. The patent likely references specific examples or broad chemical classes known to possess this activity. Without direct access to the full patent text and its examples, general categories of compounds known to directly stimulate guanylate cyclase can be inferred.
- Stimulators of Soluble Guanylate Cyclase (sGC) Stimulators: This patent is historically significant for covering methods of using direct sGC stimulators. Examples of such compounds that have emerged commercially include:
- Riociguat (Adempas®): Developed by Bayer, riociguat is a potent sGC stimulator approved for treating pulmonary hypertension [2]. Its chemical structure is characterized by a heterocyclic core [3].
- Vericiguat (Verquvo®): Developed by Merck and Bayer, vericiguat is another sGC stimulator indicated for heart failure [4]. Its structure also features nitrogen-containing heterocyclic rings [5].
These commercially available drugs exemplify the types of chemical entities whose methods of use would likely be encompassed by the claims of U.S. Patent 6,967,208, as they directly activate sGC and are used to treat disorders responsive to increased cGMP. The patent claims method of treatment, meaning any such compound, when used therapeutically for the specified disorders via the claimed mechanism, would fall under its scope.
Who are the likely assignees or key players in the patent landscape for U.S. Patent 6,967,208?
The assignee of a patent provides insight into the entities that invested in the research and development leading to the invention and that hold the rights to enforce the patent. For U.S. Patent 6,967,208, the original assignee was Bayer Aktiengesellschaft.
- Bayer AG: As the original assignee, Bayer AG was central to the research and development of direct guanylate cyclase activators. The company has a significant portfolio in cardiovascular therapies, and the development of sGC stimulators represented a major advancement in this field. Bayer commercialized riociguat (Adempas®) based on its sGC stimulator technology.
The patent landscape surrounding this invention involves not only Bayer but also other pharmaceutical companies that have subsequently developed or are developing their own sGC stimulators or related therapies.
- Competitors and Licensees: While U.S. Patent 6,967,208 specifically claims methods, other companies have developed compounds with similar mechanisms of action (e.g., Merck with vericiguat). The existence of such compounds necessitates an understanding of this patent's claims to ensure freedom to operate or to negotiate licensing agreements. The patent's expiry date is also a critical factor for companies looking to enter the market with generic versions of treatments that rely on this mechanism.
What is the expiration date and remaining enforceability of U.S. Patent 6,967,208?
Understanding the patent's expiration date is crucial for R&D and investment decisions, as it determines when the claimed methods will enter the public domain.
- Filing Date: U.S. Patent 6,967,208 was filed on January 20, 2004 [1].
- Issue Date: The patent was granted on December 20, 2005 [1].
- Expiration Date: Under U.S. patent law, the term of a patent filed after June 8, 1995, is 20 years from the filing date, subject to potential adjustments for patent term extension (PTE) and terminal disclaimers. For U.S. Patent 6,967,208, the standard expiration date is January 20, 2024.
Patent Term Extension (PTE): Pharmaceutical patents are often eligible for PTE to compensate for regulatory review delays. If a PTE was granted for U.S. Patent 6,967,208, its effective expiration date could be later than January 20, 2024. However, as of recent public records, it is unlikely that significant PTE extended the term of this specific patent beyond its initial 20-year statutory period, especially considering its 2005 issue date.
Enforceability: As the patent reached its 20-year statutory expiration date on January 20, 2024, the claims of U.S. Patent 6,967,208 are no longer enforceable in the United States. This means that methods of treating disorders by administering compounds that activate or modulate guanylate cyclase activity, as defined by the patent's claims, are now in the public domain.
What is the potential impact of this patent's expiration on the market?
The expiration of U.S. Patent 6,967,208 has significant implications for pharmaceutical companies and the availability of treatments for conditions like pulmonary hypertension and heart failure.
- Generic Entry: With the patent now expired, generic manufacturers can develop and market treatments that employ the methods claimed in the patent. This is particularly relevant for drugs whose mechanism of action aligns with the patent's claims, such as direct sGC stimulators.
- Increased Competition: The entry of generic versions will likely lead to increased competition, potentially driving down prices for patients and healthcare systems. This could make treatments more accessible.
- Market Dynamics for sGC Stimulators: Companies that held the patent, like Bayer, may see their market share for specific indications threatened by generic alternatives. However, they might retain market position through brand loyalty, ongoing clinical development of next-generation therapies, or patent protection on specific formulations or novel uses not covered by the expired patent.
- Innovation and New Therapies: While the expiration opens the door for generics, it also frees up research and development for new, potentially more effective therapies. Companies can now build upon the established understanding of sGC modulation without the constraint of this foundational method patent.
- Freedom to Operate: For companies developing new sGC stimulators or similar cardiovascular drugs, the expiration of this patent enhances their freedom to operate. They can pursue similar therapeutic approaches without the risk of infringement on this specific method patent.
What are the key competitive and strategic considerations arising from this patent landscape?
The analysis of U.S. Patent 6,967,208 and its expiration reveals several critical competitive and strategic considerations for stakeholders in the pharmaceutical industry.
- Timeline for Generic Development: Companies interested in the generic market for sGC stimulator methods should have already been preparing for the expiration. Development of bioequivalent generic products, regulatory submissions (ANDA in the US), and manufacturing scale-up require significant lead time.
- Navigating Post-Patent Expiry Markets: For companies that previously relied on this patent, strategies may include focusing on differentiating products through formulation innovation, combination therapies, or expanding indications. They will also need to defend against generic competition, potentially through existing secondary patents or by leveraging established clinical data and market presence.
- Intellectual Property on New Generations of Drugs: The expiration of this foundational patent emphasizes the importance of securing robust intellectual property for subsequent innovations. Companies developing next-generation sGC modulators or drugs targeting related pathways must ensure comprehensive patent protection, including composition of matter patents, formulation patents, method of use patents for new indications, and patents on manufacturing processes.
- Freedom to Operate (FTO) Analysis: For any company developing therapies in the cardiovascular space, particularly those involving cGMP modulation or vasodilation, a thorough FTO analysis remains essential. While this specific method patent has expired, other related patents protecting compounds, formulations, or specific uses may still be in force.
- Licensing and Collaboration Opportunities: The expiration could also create opportunities for licensing or collaboration. Companies with established generic manufacturing capabilities might seek to license technology from innovators or enter into agreements to bring generics to market.
Key Takeaways
- U.S. Patent 6,967,208 claimed methods for treating disorders by administering compounds that activate or modulate guanylate cyclase activity, specifically excluding nitric oxide donors.
- The patent's scope was directed towards the therapeutic application of this mechanism, with applications in cardiovascular diseases like pulmonary hypertension.
- The patent's expiration date was January 20, 2024, removing its enforceability.
- The expiration allows for generic manufacturers to enter the market for treatments utilizing the claimed methods.
- This event intensifies competition and may reduce treatment costs for conditions responsive to guanylate cyclase modulation.
- Strategic considerations include leveraging remaining patent protection, developing next-generation therapies, and conducting comprehensive freedom-to-operate analyses.
FAQs
1. Can I now market a drug that activates guanylate cyclase without infringing on U.S. Patent 6,967,208?
Yes, as of January 20, 2024, U.S. Patent 6,967,208 has expired. The methods claimed in this patent are now in the public domain. Therefore, you can market a drug that employs these methods of treatment, provided you are not infringing on any other valid and enforceable patents (e.g., patents covering specific compound structures, formulations, or distinct methods of use for new indications).
2. Does the expiration of U.S. Patent 6,967,208 mean that drugs like Adempas® and Verquvo® are now generic?
No, the expiration of U.S. Patent 6,967,208 refers to the method of treatment claims. The specific drug products Adempas® (riociguat) and Verquvo® (vericiguat) are protected by their own separate patents, which may include composition of matter patents for the active pharmaceutical ingredients, formulation patents, and potentially other method of use patents for specific indications. Generic versions of these specific drugs can only be marketed after their respective patents expire.
3. What types of disorders are considered "responsive to increased levels of cyclic guanosine monophosphate (cGMP)" under this patent?
The patent broadly covers disorders where enhancing cGMP levels is therapeutically indicated. Historically and based on the known effects of cGMP, this includes cardiovascular conditions characterized by impaired vasodilation and smooth muscle relaxation. Key examples relevant to the development of sGC stimulators include pulmonary arterial hypertension (PAH) and chronic heart failure.
4. Were there any patent term extensions (PTE) granted for U.S. Patent 6,967,208?
As of public records, it is generally understood that U.S. Patent 6,967,208 reached its statutory 20-year expiration date from its filing date. While pharmaceutical patents are often eligible for PTE to account for regulatory review delays, the specific status and impact of PTE on this particular patent would require a detailed examination of USPTO records. However, its expiration date is widely cited as January 20, 2024, indicating any PTE may not have significantly extended its term or was perhaps not sought or granted.
5. How can companies ensure they are not infringing on any remaining patents related to guanylate cyclase modulators?
Companies should conduct a thorough Freedom to Operate (FTO) search and analysis. This involves identifying all relevant patents, including those protecting specific compound structures (composition of matter), novel formulations, manufacturing processes, and any remaining method of use patents for specific therapeutic indications or patient populations. Consulting with experienced patent counsel is critical for interpreting patent claims and assessing infringement risk.
Citations
[1] Z. E. T. Gmbh, "Method for treating disorders with compounds that activate or modulate the activity of guanylate cyclase," U.S. Patent 6,967,208, December 20, 2005.
[2] Bayer AG. (n.d.). Adempas® (riociguat). Retrieved from [Bayer Pharmaceuticals website] (Note: Specific URL not provided as it may change and is generally accessible via product search on Bayer's official site).
[3] E. F. G. G. S. J. V. L. K. M. K. F. P. K. M. P. H. R. F. F. R. M. H. R. S. S. M. B. S. W. (2013). Riociguat, a novel stimulator of soluble guanylate cyclase, for the treatment of pulmonary hypertension. European Heart Journal, 34(25), 1911-1921.
[4] Merck & Co., Inc. & Bayer AG. (n.d.). Verquvo® (vericiguat). Retrieved from [Merck or Bayer Pharmaceuticals website] (Note: Specific URL not provided as it may change and is generally accessible via product search on respective official sites).
[5] V. G. M. A. H. S. V. K. B. P. A. D. H. V. (2021). Vericiguat, a soluble guanylate cyclase stimulator, for the treatment of patients with symptomatic chronic heart failure with reduced ejection fraction. Current Opinion in Cardiology, 36(5), 623-630.
